Cyclodextrin polymer improves atherosclerosis therapy and reduces ototoxicity

Cited 2 time in webofscience Cited 0 time in scopus
  • Hit : 81
  • Download : 0
DC FieldValueLanguage
dc.contributor.authorKim, Heegonko
dc.contributor.authorHan, Junheeko
dc.contributor.authorPark, Ji-Hoko
dc.date.accessioned2020-03-27T05:20:11Z-
dc.date.available2020-03-27T05:20:11Z-
dc.date.created2020-03-23-
dc.date.issued2020-03-
dc.identifier.citationJOURNAL OF CONTROLLED RELEASE, v.319, pp.77 - 86-
dc.identifier.issn0168-3659-
dc.identifier.urihttp://hdl.handle.net/10203/273694-
dc.description.abstractRecently, cyclodextrin (CD) has shown the potential for effective treatment of atherosclerotic plaques in mice by solubilizing plaque cholesterol. While promising as a new therapy for atherosclerosis, poor pharmacokinetics and ototoxicity of CD pose a therapeutic challenge. Thus far, however, there has been no attempts to overcome such limitations. Here, we showed that cyclodextrin polymer (CDP) with a diameter of similar to 10 nm exhibits outstanding pharmacokinetics and plaque targeting efficacy compared to a monomeric CD. Furthermore, we found out that CDP does not induce plasma membrane disruption as opposed to CD, which eliminated cytotoxicity and hemolytic activity of CD. In a mouse model of atherosclerosis, subcutaneous injections of beta-cyclodextrin polymer (beta CDP) significantly inhibited plaque growth compared to monomeric hydroxypropyl-beta-cyclodextrin (HP beta CD) at the same dose (1 g/kg). More importantly, beta CDP did not induce significant ototoxicity at a high-dose (8 g/kg) where HP beta CD reduced the outer hair cell content by 36%. These findings suggest that the polymerization of CD can overcome major limitations of CD therapy for treatment of atherosclerosis.-
dc.languageEnglish-
dc.publisherELSEVIER-
dc.titleCyclodextrin polymer improves atherosclerosis therapy and reduces ototoxicity-
dc.typeArticle-
dc.identifier.wosid000515538300006-
dc.identifier.scopusid2-s2.0-85076855163-
dc.type.rimsART-
dc.citation.volume319-
dc.citation.beginningpage77-
dc.citation.endingpage86-
dc.citation.publicationnameJOURNAL OF CONTROLLED RELEASE-
dc.identifier.doi10.1016/j.jconrel.2019.12.021-
dc.contributor.localauthorPark, Ji-Ho-
dc.contributor.nonIdAuthorHan, Junhee-
dc.description.isOpenAccessN-
dc.type.journalArticleArticle-
dc.subject.keywordAuthorAtherosclerosis-
dc.subject.keywordAuthorCyclodextrin polymer-
dc.subject.keywordAuthorPlaque therapy-
dc.subject.keywordAuthorOtotoxicity-
dc.subject.keywordPlusNIEMANN-PICK-DISEASE-
dc.subject.keywordPlusBETA-CYCLODEXTRIN-
dc.subject.keywordPlusCHOLESTEROL EXTRACTION-
dc.subject.keywordPlusCARDIOVASCULAR-DISEASE-
dc.subject.keywordPlus2-HYDROXYPROPYL-BETA-CYCLODEXTRIN-
dc.subject.keywordPlusDERIVATIVES-
dc.subject.keywordPlusPROGRESSION-
dc.subject.keywordPlusCANCER-
Appears in Collection
BiS-Journal Papers(저널논문)
Files in This Item
There are no files associated with this item.
This item is cited by other documents in WoS
⊙ Detail Information in WoSⓡ Click to see webofscience_button
⊙ Cited 2 items in WoS Click to see citing articles in records_button

qr_code

  • mendeley

    citeulike


rss_1.0 rss_2.0 atom_1.0